Tyme Technologies, Inc. (TYME), relating to its merger with Syros Pharmaceuticals, Inc. TYME shareholders are expected to receive 0.43 shares of Syros per share they own.
Tyme Technologies, Inc. (TYME), relating to its merger with Syros Pharmaceuticals, Inc. TYME shareholders are expected to receive 0.43 shares of Syros per share they own.